Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $1.1 billion.

  • IDEAYA Biosciences' Liabilities and Shareholders Equity fell 131.37% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.4 billion, marking a year-over-year increase of 319.17%. This contributed to the annual value of $1.1 billion for FY2025, which is 131.37% down from last year.
  • According to the latest figures from Q4 2025, IDEAYA Biosciences' Liabilities and Shareholders Equity is $1.1 billion, which was down 131.37% from $1.2 billion recorded in Q3 2025.
  • Over the past 5 years, IDEAYA Biosciences' Liabilities and Shareholders Equity peaked at $1.2 billion during Q3 2024, and registered a low of $326.1 million during Q1 2021.
  • In the last 5 years, IDEAYA Biosciences' Liabilities and Shareholders Equity had a median value of $530.2 million in 2023 and averaged $687.1 million.
  • In the last 5 years, IDEAYA Biosciences' Liabilities and Shareholders Equity soared by 22035.94% in 2021 and then tumbled by 441.47% in 2025.
  • Over the past 5 years, IDEAYA Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $381.3 million in 2021, then rose by 1.74% to $388.0 million in 2022, then skyrocketed by 67.36% to $649.3 million in 2023, then surged by 73.12% to $1.1 billion in 2024, then fell by 1.31% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.0 billion during Q2 2025.